Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D replacement therapy for ME/CFS after PASC or COVID-19 vaccination
jRCTs041240135Completed
- Sponsor
- Japanese Society for Vaccine-related Complications
- Start
- Dec 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of alfacalcidol and vitamin d in myalgic encephalomyelitis (ME) (2 arms), sponsored by Japanese Society for Vaccine-related Complications. Primary endpoint: Change from screening in number of ME/CFS symptoms at 12 weeks. Started Dec 2024; status: completed.
02
Drugs
alfacalcidolvitamin d
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on jRCTs041240135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240135.